CVAC - Why did CureVac stock slip today? Declining market for COVID vaccines
- CureVac ( NASDAQ: CVAC ) shares dropped ~7% Tuesday likely due to comments Pfizer ( PFE ) made earlier in the day that it expects a 64% drop in revenue from its COVID-19 vaccine.
- CureVac ( CVAC ) is developing its own mRNA COVID vaccine, and reported positive phase 1 results .
- However, given Pfizer's ( PFE ) comments on a declining COVID vaccine market, CureVac's ( CVAC ) shot could become available too little, too late.
- In 2023, Pfizer ( PFE ) expects demand for its COVID vaccine of 65M , compared to 92M doses in 2022.
- Check out Seeking Alpha contributor Derek Lowe's recent assessment of CureVac ( CVAC ).
For further details see:
Why did CureVac stock slip today? Declining market for COVID vaccines